semaglutide and prostate cancer Targeting obesity, metabolic syndrome, cancer: GLP-1 agonists as emerging therapeutic agents | Discover Oncology GLP-1s appear to cut cancer

Published by Yan Xie, Yaeyoung Choi and Ziyad Al-Aly in Nature Medicine.

Berg WA, Seitzman RL, Pushkin J

Given the surging popularity of obesity management drugs in recent years, the FDA put out a warning singling out compounded GLP-1s, calling them risky for patients. The agency said it had received hundreds of reports of adverse events linked to compounded semaglutide (392) and tirzepatide (215) as of Nov

Long-term safety data still pending

Others discover that the savings evaporate when accounting for testing costs, shipping delays, and occasional batches that fail to meet specifications

These drugs are not magic and not without risks